Index RUT
P/E -
EPS (ttm) -4.99
Insider Own 64.50%
Shs Outstand 29.39M
Perf Week 7.00%
Market Cap 388.29M
Forward P/E -
EPS next Y -3.66
Insider Trans 0.30%
Shs Float 20.73M
Perf Month 28.13%
Income -238.30M
PEG -
EPS next Q -1.07
Inst Own 38.01%
Short Float / Ratio 20.01% / 12.73
Perf Quarter -13.30%
Sales 1.85M
P/S 209.89
EPS this Y 11.05%
Inst Trans -0.67%
Short Interest 4.15M
Perf Half Y -37.38%
Book/sh 4.35
P/B 1.53
EPS next Y 22.57%
ROA -46.94%
Target Price 19.90
Perf Year -66.38%
Cash/sh 6.64
P/C 1.00
EPS next 5Y -
ROE -81.88%
52W Range 3.81 - 27.92
Perf YTD -60.91%
Dividend -
P/FCF -
EPS past 5Y -71.19%
ROI -82.50%
52W High -76.18%
Beta 0.19
Dividend % -
Quick Ratio 9.27
Sales past 5Y 0.00%
Gross Margin -547.54%
52W Low 74.54%
ATR 0.69
Employees 258
Current Ratio 9.27
Sales Q/Q 53.78%
Oper. Margin -13755.05%
RSI (14) 59.06
Volatility 13.55% 13.47%
Optionable Yes
Debt/Eq 0.16
EPS Q/Q 21.06%
Profit Margin -12873.96%
Rel Volume 1.20
Prev Close 7.00
Shortable Yes
LT Debt/Eq 0.14
Earnings Nov 13 AMC
Payout -
Avg Volume 325.99K
Price 6.65
Recom 1.80
SMA20 15.76%
SMA50 23.15%
SMA200 -33.01%
Volume 390,278
Change -5.00%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-07-23 Downgrade
H.C. Wainwright
Buy → Neutral
$11 → $7
Nov-09-22 Resumed
Jefferies
Buy
$61 → $55
Oct-17-22 Initiated
JP Morgan
Neutral
$27
Aug-29-22 Initiated
BofA Securities
Buy
$34
Dec-13-21 Downgrade
RBC Capital Mkts
Outperform → Sector Perform
$51
Nov-05-21 Upgrade
Wedbush
Neutral → Outperform
Aug-26-21 Initiated
Morgan Stanley
Overweight
$100
Jan-29-21 Initiated
RBC Capital Mkts
Outperform
$121
Jan-19-21 Reiterated
H.C. Wainwright
Buy
$88 → $114
Dec-22-20 Downgrade
Wedbush
Outperform → Neutral
Jul-17-20 Initiated
Robert W. Baird
Outperform
$90
Jul-01-20 Initiated
H.C. Wainwright
Buy
$88
May-28-20 Initiated
SunTrust
Buy
$86
Apr-22-20 Initiated
Wedbush
Outperform
$73
Oct-14-19 Initiated
Stifel
Buy
$32
Oct-14-19 Initiated
Piper Jaffray
Overweight
$26
Oct-14-19 Initiated
Jefferies
Buy
$25
Oct-14-19 Initiated
Guggenheim
Buy
$30
Show Previous Ratings
Dec-08-23 04:09AM
Dec-06-23 02:44AM
Dec-05-23 04:01PM
Dec-01-23 05:32AM
Nov-27-23 03:52AM
02:46AM
Loading…
Nov-22-23 02:46AM
Nov-21-23 02:48AM
Nov-16-23 09:55AM
Nov-14-23 07:28PM
Nov-13-23 04:10PM
03:49AM
Nov-07-23 07:00AM
Oct-25-23 02:46AM
Oct-23-23 02:48AM
Oct-20-23 09:29AM
07:29AM
Loading…
Oct-05-23 07:29AM
Oct-03-23 04:05PM
Sep-20-23 04:36AM
Sep-06-23 07:00AM
Aug-10-23 08:59PM
Aug-03-23 05:25PM
04:10PM
Jul-05-23 06:46AM
Jul-03-23 04:01PM
Jun-30-23 09:48AM
Jun-22-23 08:14PM
07:58AM
Jun-21-23 05:17PM
Jun-02-23 05:30PM
Jun-01-23 07:00AM
07:00AM
Loading…
May-31-23 07:00AM
May-30-23 07:00AM
May-25-23 11:58AM
May-12-23 10:15AM
09:05AM
May-02-23 07:00AM
Apr-28-23 11:50AM
Apr-19-23 07:00AM
Apr-13-23 04:05PM
Apr-06-23 12:23PM
Apr-01-23 09:17AM
Mar-30-23 06:05PM
04:05PM
Mar-27-23 07:00AM
Feb-02-23 07:00AM
Jan-17-23 07:00AM
Jan-09-23 07:00AM
Jan-03-23 07:00AM
Dec-11-22 10:00AM
Dec-01-22 07:00AM
Nov-16-22 06:37AM
Nov-08-22 07:00AM
Nov-03-22 10:25AM
09:05AM
Nov-02-22 04:05PM
Oct-27-22 02:06PM
Sep-06-22 07:00AM
Aug-08-22 06:45PM
04:10PM
Jul-04-22 02:04PM
Jun-01-22 07:00AM
May-20-22 12:07PM
May-10-22 07:00AM
May-09-22 04:16PM
May-06-22 07:00AM
Apr-09-22 09:35AM
Apr-06-22 04:39PM
Apr-05-22 04:56PM
Mar-30-22 03:06PM
02:14PM
01:29PM
11:57AM
12:56AM
Mar-29-22 11:41AM
09:00AM
08:54AM
07:59AM
07:41AM
06:01AM
02:00AM
Feb-09-22 03:34PM
07:00AM
Feb-03-22 04:05PM
Jan-10-22 10:00AM
Jan-05-22 07:00AM
Dec-13-21 09:43AM
07:08AM
Dec-11-21 01:31PM
Dec-09-21 07:36AM
Dec-08-21 07:00AM
Dec-06-21 04:05PM
Nov-10-21 04:05PM
11:15AM
Nov-08-21 07:00AM
Nov-04-21 11:25AM
09:21AM
Oct-11-21 04:05PM
Oct-06-21 11:44AM
Sep-23-21 04:05PM
Sep-10-21 09:01AM
IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The firm's product pipeline includes IGM-2323, which is a CD20 x CD3 bispecific IgM antibody designed to treat patients with B cell Non-Hodgkin's lymphoma and other B cell malignancies, IGM-8444, which is an IgM antibody targeting Death Receptor 5 for the treatment of patients with solid and hematologic malignancies, and IGM-7354, which will target the delivery of IL-15 with the goal of inducing immune cell stimulation and proliferation. The company was founded in 2010 and is headquartered in Mountain View, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Takimoto Chris H Chief Medical Officer Nov 29 Sale 6.21 1,180 7,331 53,562 Dec 01 07:03 PM Decker Lisa Lynn Chief Business Officer Nov 29 Sale 6.21 1,180 7,331 40,001 Dec 01 07:01 PM Gauthier George Chief Commercial Officer Nov 29 Sale 6.21 1,180 7,331 39,642 Dec 01 07:02 PM Tahir Misbah Chief Financial Officer Nov 27 Sale 5.06 1,337 6,764 49,608 Nov 29 08:49 PM Schwarzer Fred CEO and President Nov 27 Sale 5.06 1,337 6,764 120,424 Nov 29 08:48 PM Keyt Bruce Chief Scientific Officer Nov 27 Sale 5.06 933 4,720 137,125 Nov 29 08:47 PM Gauthier George Chief Commercial Officer Oct 02 Sale 7.95 935 7,430 39,082 Oct 03 07:55 PM Gauthier George Chief Commercial Officer Jul 03 Sale 9.42 936 8,818 40,017 Jul 05 09:08 PM Topsoe Jakob Haldor Director Jun 30 Buy 9.25 3,500 32,375 81,644 Jul 03 06:46 PM Topsoe Christina Teng Director Jun 30 Buy 9.32 3,000 27,957 9,800 Jul 05 09:07 PM Redmile Group, LLC Director Jun 29 Buy 9.42 80,423 757,585 2,974,186 Jul 03 09:45 PM Topsoe Jakob Haldor Director Jun 29 Buy 9.10 3,500 31,846 78,144 Jul 03 06:46 PM Redmile Group, LLC Director Jun 29 Sale 9.42 80,423 757,585 2,893,763 Jul 03 09:45 PM BEHRENS M KATHLEEN Director Jun 26 Buy 8.00 112,500 900,000 330,700 Jun 28 07:34 PM Gauthier George Chief Commercial Officer May 23 Sale 12.31 1,259 15,497 40,953 May 25 07:20 PM Decker Lisa Lynn Chief Business Officer May 23 Sale 12.31 1,259 15,497 41,181 May 25 07:20 PM Tahir Misbah Chief Financial Officer May 23 Sale 12.31 1,259 15,497 50,711 May 25 07:23 PM Takimoto Chris H Chief Medical Officer May 23 Sale 12.31 1,259 15,497 54,742 May 25 07:24 PM Schwarzer Fred CEO and President May 23 Sale 12.31 1,259 15,497 121,761 May 25 07:22 PM Keyt Bruce Chief Scientific Officer May 23 Sale 12.31 982 12,088 138,058 May 25 07:21 PM Gauthier George Chief Commercial Officer Apr 05 Sale 12.60 935 11,781 33,878 Apr 06 09:39 PM Takimoto Chris H Chief Medical Officer Mar 14 Sale 18.73 1,768 33,118 28,789 Mar 16 06:31 PM Tahir Misbah Chief Financial Officer Mar 14 Sale 18.73 1,768 33,118 25,322 Mar 16 06:30 PM Keyt Bruce Chief Scientific Officer Mar 14 Sale 18.73 1,293 24,220 90,704 Mar 16 06:30 PM Gauthier George Chief Commercial Officer Mar 14 Sale 18.73 1,061 19,875 18,563 Mar 16 06:28 PM Decker Lisa Lynn Chief Business Officer Mar 14 Sale 18.73 1,061 19,875 16,732 Mar 16 06:27 PM Keyt Bruce Chief Scientific Officer Jan 05 Option Exercise 0.93 33,756 31,393 91,997 Jan 09 06:16 PM Tahir Misbah Chief Financial Officer Dec 19 Sale 20.00 3,801 76,020 27,090 Dec 20 08:09 PM Schwarzer Fred CEO and President Dec 16 Sale 18.98 12,369 234,805 20,360 Dec 20 08:08 PM Takimoto Chris H Chief Medical Officer Dec 16 Sale 18.98 5,430 103,080 30,557 Dec 20 08:12 PM Keyt Bruce Chief Scientific Officer Dec 16 Sale 18.98 5,371 101,960 58,241 Dec 20 08:07 PM Gauthier George Chief Commercial Officer Dec 16 Sale 18.98 4,354 82,654 19,624 Dec 20 08:06 PM Decker Lisa Lynn Chief Business Officer Dec 16 Sale 18.98 2,484 47,154 17,793 Dec 20 08:05 PM Tahir Misbah Chief Financial Officer Dec 16 Sale 18.98 2,283 43,339 30,891 Dec 20 08:09 PM Keyt Bruce Chief Scientific Officer Dec 14 Option Exercise 0.93 25,000 23,250 63,612 Dec 16 07:40 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite